# Bristol-Myers Squibb: Phase 3 study closed enrollment, 606 enrolled (Relapsed or Refractory Multiple Myeloma)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) |
| NCT ID | NCT05552976 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Relapsed or Refractory Multiple Myeloma |
| Intervention types | drug |
| Target enrollment | 606 |
| Site countries | United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, China, Colombia, Denmark, Germany, Greece |
| Posted | 2022-09-23 |
| Planned start | 2023-01-10 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-24 |
| Last update posted | 2026-09-24 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 606 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05552976). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.